share_log

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $6

Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $6

Chardan Capital維持對Senti Biosciences的買入,將目標股價下調至6美元
Benzinga ·  2023/05/11 13:08

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and lowers the price target from $7 to $6.

Chardan Capital分析師Geulah Livshits維持Senti Biosciences(納斯達克股票代碼:SNTI)的買入,並將目標股價從7美元下調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論